Amiko Digital Health said today that it received CE Mark clearance to integrate its Respiro medication sensor tech with Teva Pharmaceuticals‘ (NYSE:TEVA) Spiromax inhaler, Chiesi‘s Nexthaler device and GlaxoSmithKline‘s (NYSE:GSK) Ellipta inhaler.
The company’s Respiro platform is designed to help doctors monitor, in real-time, when and how well patients are using their medications.
“Respiro’s medication sensors capture data on true adherence behavior, which better reflects real-life patient inhaler use, as compared to traditional measures of adherence,” Job van Boven, assistant professor at the University Medical Center Groningen, said in prepared remarks. “This information can help us better understand the effectiveness of an inhaled drug therapy, and support the development of personalized and cost-effective interventions promoting adherence and correct inhaler technique.”
“Receiving the CE Mark is a significant milestone toward the global commercialization of our connected inhaler technology. By successfully completing this process, Amiko has demonstrated that Respiro complies with applicable EU’s health and safety legislative requirements and it can now offer the technology for clinical and commercial use to healthcare providers and research institutions in the EU,” Federica Iovine, Amiko’s director of regulatory affairs, added.
Having nabbed CE Mark clearance, Amiko plans to start commercializing Respiro in Europe later this year.